First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis DOI Creative Commons
Jingxin Li, Yijing Tang, Qianying Chen

et al.

Medicine, Journal Year: 2024, Volume and Issue: 103(52), P. e41082 - e41082

Published: Dec. 27, 2024

For patients with human epidermal growth factor receptor 2 (HER2)-low advanced breast cancer who had failed to meet anthracycline or taxane, the application of HER2-targeted antibody-drug conjugates as second-line therapy could improve patients' outcomes, but it is unclear whether carboplatin-based first-line will benefit these patients. This retrospective study was designed explore carboplatin based treatment outcomes in HER2-low cancer, and analyze potential factors affecting efficacy prognosis. 103 HER2-negative metastatic were treated therapy. The differences progression-free survival (PFS), objective response rate (ORR), adverse events analyzed different HER2 expression subgroups. risk ratio (HR) 95% confidence interval (CI) for PFS estimated using Cox proportional models. ORR whole group 42.72% median (mPFS) 7.93 months (m). significantly higher than HER2-zero (56.4% vs 27.1%, P = .003), an independent (OR 3.478, 95%CI 1.516-7.977, especially HR-negative subgroup. mPFS longer low neutrophil-to-lymphocyte (NLR) scores those high NLR (P < .001). Multivariate analysis showed that young (age 40) .006) values .001) prognostic mPFS. main grade 3 4 reactions neutropenia (15.53%), anemia leukopenia (11.65%). chemotherapy quite active tolerable rates can be achieved. In cases where CDK4/6 inhibitors are inappropriate use due resistance endocrine urgent need short-term clinical response, remains important. When necessary consider accessibility economics patients, may provided a more convenient, cost-effective efficient option on front line. Forecasting prognosis via inflammatory index such before commencement enhance precision efficiency regimens.

Language: Английский

Prognostic Impact of HER2 Low Status in Male Breast Cancer: Prospective Cohort Analysis DOI Open Access
Atanas Ignatov,

Sina Lempfer,

József Mészáros

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(19), P. 3399 - 3399

Published: Oct. 5, 2024

Male breast cancer (MBC) is a rare disease, and the potential influence of low expression human epidermal growth factor receptor 2 (HER2 low) remains unexplored.

Language: Английский

Citations

1
First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis DOI Creative Commons
Jingxin Li, Yijing Tang, Qianying Chen

et al.

Medicine, Journal Year: 2024, Volume and Issue: 103(52), P. e41082 - e41082

Published: Dec. 27, 2024

For patients with human epidermal growth factor receptor 2 (HER2)-low advanced breast cancer who had failed to meet anthracycline or taxane, the application of HER2-targeted antibody-drug conjugates as second-line therapy could improve patients' outcomes, but it is unclear whether carboplatin-based first-line will benefit these patients. This retrospective study was designed explore carboplatin based treatment outcomes in HER2-low cancer, and analyze potential factors affecting efficacy prognosis. 103 HER2-negative metastatic were treated therapy. The differences progression-free survival (PFS), objective response rate (ORR), adverse events analyzed different HER2 expression subgroups. risk ratio (HR) 95% confidence interval (CI) for PFS estimated using Cox proportional models. ORR whole group 42.72% median (mPFS) 7.93 months (m). significantly higher than HER2-zero (56.4% vs 27.1%, P = .003), an independent (OR 3.478, 95%CI 1.516-7.977, especially HR-negative subgroup. mPFS longer low neutrophil-to-lymphocyte (NLR) scores those high NLR (P < .001). Multivariate analysis showed that young (age 40) .006) values .001) prognostic mPFS. main grade 3 4 reactions neutropenia (15.53%), anemia leukopenia (11.65%). chemotherapy quite active tolerable rates can be achieved. In cases where CDK4/6 inhibitors are inappropriate use due resistance endocrine urgent need short-term clinical response, remains important. When necessary consider accessibility economics patients, may provided a more convenient, cost-effective efficient option on front line. Forecasting prognosis via inflammatory index such before commencement enhance precision efficiency regimens.

Language: Английский

Citations

1